Dysport in Vulvodynia Phase II Study
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2022
-
- participants needed
- 180
-
- sponsor
- Ipsen
Ipsen Recruitment Enquiries
Primary Contact
James A. Simon, MD, PC (6.4 mi away) Contact
+23 other locationSummary
This study is designed to define optimal doses of Dysport and evaluate its efficacy and safety compared with placebo for the treatment of vulvodynia.
The study will consist of a dose escalation stage (Stage 1) and a dose expansion stage (Stage 2). Both Stage 1 and Stage 2 will consist of a double-blind period (with treatment cycle 1; Dysport or placebo) followed by an open label treatment period. One or two optimally safe and effective doses of Dysport selected from Stage 1 will be further investigated in the Stage 2.
Details
| Treatment | Placebo, Botulinum Toxin Type A, Botulinum Toxin Type A (Dysport) |
|---|---|
| Clinical Study Identifier | NCT03598777 |
| Sponsor | Ipsen |
| Last Modified on | 2 December 2020 |
Adding a note
Select a piece of text and start making personal notes.
Similar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer